Viewing Study NCT03618550

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:54 PM
Ignite Modification Date: 2026-02-25 @ 5:49 PM
Study NCT ID: NCT03618550
Status: RECRUITING
Last Update Posted: 2025-12-02
First Post: 2018-07-30
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hodgkin Lymphoma View
None Relapsed or Refractory Hodgkin Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Pembrolizumab View
None GVD View
None 18-160 View